The FDA has approved Caplyta as adjunctive therapy with antidepressants to treat major depressive disorder in adults, ...

The approval of medicines called second-generation antipsychotics has allowed bipolar I and some conditions that come with it to be treated. A person who has bipolar I disorder can go through various ...

The approval of medicines called second-generation antipsychotics has allowed bipolar I and other associated conditions to be treated. A person with bipolar I disorder can go through various mood ...

Changes Clinical Practice: Based on this large trial, lithium alone or a lithium-valproate combination should be used as first-line maintenance treatment for bipolar affective disorder type I instead ...

Uzedy administered once every 2 months is not recommended for the maintenance treatment of bipolar I disorder. The Food and Drug Administration (FDA) has approved Uzedy ® (risperidone extended-release ...

For many people who have bipolar I, lithium is that most elusive of pharmacological treatments, the “magic bullet”—a single intervention that completely eliminates the symptoms of a disease. Since the ...

Nearly 5 million Americans navigate the complex challenges of bipolar I disorder daily, facing dramatic shifts between manic highs and depressive lows that can derail careers, relationships and ...

The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for ...